Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Chinese Medicine
  4. Vol 5, Issue 9, 2023

Research Progress on Traditional Chinese Medicine Treatment of Primary Biliary Cholangitis

Download as PDF

DOI: 10.23977/medcm.2023.050906 | Downloads: 19 | Views: 391

Author(s)

Mengqi Li 1, Fanrong Liu 2

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
2 Yulin Traditional Chinese Medicine Hospital Affiliated to Shaanxi University of Chinese Medicine, Yulin, Shaanxi, 719051, China

Corresponding Author

Mengqi Li

ABSTRACT

Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease that mainly affects the intrahepatic interlobular bile duct cells. The incidence rate in the population is 4–30 cases per 100,000 people per year, and the mortality rate accounts for 1.6%–2.0% of deaths from liver cirrhosis. The pathogenesis of PBC is not clear, but it is mainly believed to be related to autoimmunity. This article summarizes the clinical treatment research on PBC in the past decade, analyzing and explaining the etiology and pathogenesis of PBC in traditional Chinese medicine, as well as the characteristics of traditional Chinese medicine treatment. Traditional Chinese medicine believes that in the early stage of PBC, there is liver and kidney deficiency and insufficient yin fluid; in the middle stage, there is dampness and stagnation; and in the late stage, there is liver collateral obstruction. The treatment focuses on nourishing the liver and kidneys, clearing heat and dampness, promoting blood circulation, resolving stasis, and regulating the liver and spleen. At the same time, the article points out the problems existing in the current research on traditional Chinese medicine's treatment of PBC and the prospects for future research. 

KEYWORDS

Primary biliary cholangitis; Traditional Chinese medicine treatment; Research progress

CITE THIS PAPER

Mengqi Li, Fanrong Liu, Research Progress on Traditional Chinese Medicine Treatment of Primary Biliary Cholangitis. MEDS Chinese Medicine (2023) Vol. 5: 47-55. DOI: http://dx.doi.org/10.23977/medcm.2023.050906.

REFERENCES

[1] Gideon M Hirschfield, et al. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis [J]. Journal of Hepatology, 2017, 67(1):145-172. 
[2] Chen Chengwei, Cheng Jun, Dou Xiaoguang, et al. Consensus on diagnosis and treatment of primary biliary cirrhosis (also known as primary biliary cholangitis) (2015)[J]. Journal of Hepatobiliary Diseases, 2015, 31(12):1980-1988. 
[3] Wang Dan, Liu Wenjin. A case of primary biliary cholangitis treated by traditional Chinese medicine [J]. Shanxi Chinese Medicine, 2010, 26(7):25. 
[4] Han Lei, Zhang Jing. Analysis on the characteristics of drugs for the treatment of intrahepatic cholestasis syndrome [J]. Liaoning Journal of Traditional Chinese Medicine, 2005, 32(11):113-114. (in Chinese)
[5] Chen Wenlin, Ran Yun, Wu Qikai, et al. Two cases of Yang Da Guo's treatment of primary biliary cirrhosis [J]. International Journal of Chinese Medicine, 2014. 36(4):365-367. (in Chinese)
[6] Lu Dianqiang, Shao Ming. Traditional Chinese medicine differentiation and treatment of primary biliary cirrhosis [J]. Journal of Liaoning University of Traditional Chinese Medicine, 2012(1):185-187. 
[7] Du Hongbo, Jiang Yuyong. Comparative study of literature syndrome factors between primary biliary cirrhosis and chronic viral hepatitis B [J]. Journal of Shandong University of Traditional Chinese Medicine, 2019, 43(3):224-229. 
[8] Fan Xingliang, Zhu Junfeng. Wang Lingtai's experience in treating primary biliary cirrhosis (cholangitis) [J]. Shanghai Journal of Traditional Chinese Medicine, 2016, 50(8):1-4. 
[9] Bao Ting, Zheng Chao, Zhu Xiaojun, et al. Experience of Professor Wang Lingtai in the treatment of primary biliary cholangitis [J]. Journal of Shanghai University of Traditional Chinese Medicine, 2016, 30(3):1-3. 
[10] Xu Ying, Mu Yongping. Experience of Liu Ping in the treatment of primary biliary cirrhosis [J]. Shanghai Journal of Traditional Chinese Medicine, 2015, 49(12):1-4. 
[11] Hao J, Zhou Y, Xing F, et al. Analysis of TCM syndrome of primary biliary cholangitis [J]. Global Chinese Medicine, 2017, 10(12):1438-1442. (in Chinese)
[12] Liu Benyong, Chen Shaoyu, Li Dan. Feng Xinghua's experience in treating primary biliary cirrhosis [J]. Chinese Journal of Traditional Chinese Medicine, 2015, 56(6):462-465. (in Chinese)
[13] Ren Meng, Zheng Yajiang, Zhu Junfeng. TCM syndrome differentiation and classification of primary biliary cirrhosis [J]. Jilin Chinese Medicine, 2016, 36(7):678-681. (in Chinese)
[14] Du H B, Jiang Y Y, Xue Y C, et al. Investigation of TCM syndromes in 96 patients with primary biliary cirrhosis [J]. Journal of Traditional Chinese Medicine, 2017, 58(7):575-578. 
[15] Zheng Yueqi, Chen Jianjie, Chen Yiyun, et al. Literature analysis of traditional Chinese medicine syndrome types and syndrome elements distribution characteristics of primary biliary cholangitis [J]. Journal of Clinical Hepatobiliary Diseases, 2018, 34(4):814-819. (in Chinese)
[16] He Weili, Xu Guangfu. Lidan Tongluo Jiedu prescription combined with ursodeoxycholic acid in the treatment of primary biliary cirrhosis [J]. Chinese Journal of Modern Pharmacology, 2014, 8(23):108-109. 
[17] Wang XX, Zhu WP. Investigation on constitution and syndrome type of 93 patients with primary biliary cholangitis [J]. Clinical Research of Chinese Medicine, 2017, 9(33):1-4. 
[18] Shi Wenli, Liu Fei-Fei, Zhang Xiao-feng, et al. TCM syndromes and characteristics of primary biliary cirrhosis Analysis of curative effect [J]. Journal of Integrative Chinese and Western Medicine Hepatology, 2014, 24(4):225-226, 253. 
[19] Xiao Linghui, Hu Xiaoyu. Clinical observation of Lidan Yanggan prescription combined with ursodeoxycholic acid capsule in treatment of primary biliary cirrhosis [J]. Beijing Traditional Chinese Medicine, 2018, 37(6):553-555+561. 
[20] Tian Fengliang, Li Xiaoqing. Clinical observation of Yigan Zhiyang Decoction in the treatment of hepatobiliary pruritus induced by liver deficiency and wind [J]. Chinese Journal of Hepatology, 2013, 23(6):353-354+358. 
[21] Lu Dingbo, Jiang Shiyi, Li Hanmin. Clinical analysis of Diwu Yanggan prescription combined with ursodeoxycholic acid in the treatment of primary biliary cholangitis [J]. Chinese Journal of Hepatology, 2019, 29 (1):13-15. 
[22] Chen Guirong, Dong Qingyang, Zhou Hao. Shugan Jianpi Decoction treating 45 cases of liver depression and spleen deficiency syndrome of primary biliary cirrhosis [J]. Global Journal of Chinese Medicine, 2019, 13(4):744-747. (in Chinese)
[23] Zeng Wuwu, Wu Xuejie. Effects of Hugan Zhuyu Decoction combined with UDCA on immunoglobulin and T lymphocyte subpopulation in patients with primary biliary cirrhosis [J]. Chinese Journal of General Medicine, 2019, 17(3):464-467. 
[24] Sun Dazhi, Ma Youbing. The regulatory effect of Shugan Huoxue prescription on Th17/Treg cells in patients with primary biliary cirrhosis with liver-stagnation and spleen-deficiency [J]. Sichuan Traditional Chinese Medicine, 2018, 36(4):113-116. 
[25] Gan Xia, Zhao Xinfang, Lin Hong, et al. Effect of Qingying Huoxue Decoction on dampness-heat type of liver and bile in patients with primary biliary cirrhosis and its influence on Thl7/Treg balance in peripheral blood [J]. Chinese Journal of Experimental Formulae, 2016, 22(11):161-164. 
[26] Zheng Yueqi, Ling Qihua, Chen Yiyun, et al. Chen Jianjie's experience in treating primary biliary cirrhosis [J]. Shandong Journal of Traditional Chinese Medicine, 2017, 36(12):1052-1054. 
[27] Liu Quanzhong, Yan Le, ZHAO Wenxia. Preliminary study of Yinshao Erhuang Decoction in treating primary biliary cholangitis and regulating Treg/TGF-B axis [J]. Chinese Journal of Hepatology, 2019, 29(1):10-12. 
[28] Liu Quanzhong, Li Suling, Hao Yaokun. Treating 25 cases of primary biliary cirrhosis with Huoxue Yangzheng method [J]. Journal of Integrated Chinese and Western Medicine Hepatology, 2016, 26(4):244-246. 
[29] Liu Guangzheng. Clinical study on the treatment of autoimmune liver disease by supplementing Qi and detoxifying Tongluo [D]. Beijing University of Chinese Medicine, 2016. 
[30] Bai Zhiqin, Song Huiying, Wu Ruiqing, et al. Treating 28 cases of primary biliary cirrhosis with Buqi Huoxue decoction [J]. Journal of Integrated Chinese and Western Medicine Hepatology, 2017, 27(1):56-58. (in Chinese)
[31] Xu Shucai. Qingying Huoxue Decoction treating 56 cases of middle and late stage primary biliary cirrhosis in middle-aged women [J]. Global Chinese Medicine, 2016, 9 (6):733-736. 
[32] Lin Lin, Yu Xiaofang, Chen Guoliang. Clinical observation of Qiwei Huayxi Decoction combined with ursodeoxycholic acid in the treatment of primary biliary cirrhosis with spleen deficiency and blood stasis in stage 2 and Stage 3 [J]. Chinese Medicine Bulletin, 2015, 14(5):50-52. 
[33] Shi Zhen, Zheng Yueqi, Chen Yiyun, et al. Effect of Chinese patent medicine combined with ursodeoxycholic acid on primary biliary cholangitis: a meta-analysis [J]. Review of Chinese Medicine, 2019, 2S (23):88-92. 
[34] Li Q, Zhou L, Zhang J, et al. Therapeutic effect of ursodeoxycholic acid combined with immunosuppressants in the treatment of autoimmune hepatitis [J]. Chinese Journal of Digestion, 2015, 35(1):767-770. 
[35] Li Xiaochuan. Effects of prednisone acetate combined with ursodeoxycholic acid on humoral immunity and liver function in patients with autoimmune hepatitis [J]. Chinese Journal of Medicine and Clinic, 2019, 20(9):1530-1532. 
[36] Cao Delong, Cao Haifang, Wang Xiaoxia, et al. Clinical study of ursodeoxycholic acid capsule combined with diammonium glycyrrhizinate in the treatment of autoimmune hepatitis [J]. Modern Medicine and Clinic, 2018, 33(10):2615-2619. 
[37] Shang Rui, Wu Jun. Preliminary clinical study of Tripterygium glycosides, azathioprine combined with diammonium glycyrrhizinate in the treatment of autoimmune hepatitis [J]. Journal of Practical Hepatology, 2017, 20(3):290-293. 
[38] Zhou Yanyi, Yang Can. Preliminary study on therapeutic effect of Tripterygium wilfordia polyglycoside tablets combined with magnesium isoglycyrrhizinate in the treatment of patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2019, 22(3):365-368. 
[39] Zong Y. Clinical experience of 22 cases of primary biliary cirrhosis treated by integrated Chinese and Western medicine [J]. Shi Zhen Chinese Medicine, 2008, 19(10):255. 
[40] Zhao L. The clinical study on the treatment of primary biliary cirrhosis by addition and reduction of Lidan and Luofang combined with ursodeoxycholic acid [D]. Nanjing University of Chinese Medicine. 2013. 
[41] Li Shuangquan, Lin Li, Ren Shuping. Study on wind-pathogenic effects in the pathogenesis of autoimmune liver disease [J]. World Journal of Integrated Traditional Chinese and Western Medicine, 2014, 9(12):1355-1363. (in Chinese)
[42] Liu Benyong, Chen Shaoyu, Li Dan, et al. Feng Xinghua's experience in treating primary biliary cirrhosis [J]. Chinese Journal of Traditional Chinese Medicine. 2015, 56 (6) : 462-464. 
[43] Jin H. Summary of Professor Qian Ying's academic thought and clinical experience, and theoretical and clinical study on the compensatory stage of liver cirrhosis treated with hemotherapy [D]. Beijing University of Chinese Medicine, 2016.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4233
Visits: 167691

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.